Long-Term Complete Remission of a Patient With Double-Hit Diffuse Large B-Cell Lymphoma Treated by Chemoimmunotherapy and Chinese Herbal Medicine

Perspectives on chemotherapy for the management of double-hit lymphoma

(2020) Taha Al-Juhaishi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Antitumor potential of Hedyotis diffusa Willd: A systematic review of bioactive constituents and underlying molecular mechanisms

(2020) Xinru Han et al.   BIOMEDICINE & PHARMACOTHERAPY

Salvianolic acid A inhibits the growth of diffuse large B-cell lymphoma through MAPK pathways

(2020) Shuting Li et al.   EXPERIMENTAL HEMATOLOGY

Epidemiology and Etiology of Leukemia and Lymphoma

(2019) Jordan A. Baeker Bispo et al.   Cold Spring Harbor Perspectives in Medicine

Poor outcomes for double‐hit lymphoma patients treated with curative‐intent second‐line immunochemotherapy following failure of intensive front‐line immunochemotherapy

(2019) Daniel J. Landsburg et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

(2018) Kieron Dunleavy et al.   Lancet Haematology

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

(2014) A. M. Petrich et al.   BLOOD

Double-hit primary unilateral adrenal lymphoma with good outcome

(2014) Olivera Markovic et al.   Vojnosanitetski Pregled